Derek H. Tang, PhD, BSPharm

For patients with psoriasis and/or psoriatic arthritis, actual-to-expected dosing ratios and costs were lower for etanercept than for ustekinumab.

Medication compliance is associated with lower overall and disease-related healthcare costs in patients with moderate to severe rheumatoid arthritis receiving biologic therapies.

This study applied a validated algorithm to estimate the effectiveness and costs of the index biologic used by 4696 US veterans with rheumatoid arthritis.